Physician profile
Gregory Sutton
NPI 1255575270
$5,323.02
in general payments reported to CMS, 2019-2025
51 companies · $3,017 in 2025
The $3,017 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $91.20 · 2021: $11.92 · 2023: $252 · 2024: $1,545 · 2025: $3,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $38.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,775.32 |
| Education | $38.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $397.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $271.92 | 2019-2025 | Tagrisso, Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $268.46 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Daiichi Sankyo INC. | $250.42 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $229.75 | 2019-2025 | Padcev, Vyloy, Xospata |
| Pfizer INC. | $227.15 | 2019-2025 | |
| Gilead Sciences, INC. | $216.52 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $207.24 | 2023-2025 | Libtayo |
| Glaxosmithkline, LLC. | $202.88 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Deciphera Pharmaceuticals INC. | $193.54 | 2024-2025 | Qinlock, Romvimza |
| Exelixis INC. | $182.02 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $154.92 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $154.55 | 2024-2025 | Rybrevant, Talvey, Tecvayli |
| Lilly USA, LLC | $145.21 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $141.73 | 2019-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $128.38 | 2024-2025 | Monjuvi, Zynyz, Jakafi |
| Alexion Pharmaceuticals, INC. | $123.54 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $120.17 | 2024-2025 | Itovebi, Venclexta, Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $113.25 | 2023-2025 | |
| Eisai INC. | $101.52 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.39 | 2019-2025 | Opdivo |
| Genzyme Corporation | $93.84 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $91.69 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $91.66 | 2023-2025 | Xermelo, Zoladex |
| Pharmaessentia USA Corporation | $84.65 | 2024-2025 | Besremi |
| Geron Corporation | $79.61 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $79.43 | 2023-2025 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.05 | 2024-2025 | Gilotrif |
| Legend Biotech USA INC. | $64.53 | 2025 | Carvykti |
| Genmab U.S., INC. | $52.57 | 2024-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $49.50 | 2025 | Onivyde |
| Taiho Oncology, INC. | $49.31 | 2024 | |
| Seagen INC. | $46.62 | 2023 | Tukysa |
| Stemline Therapeutics INC. | $45.76 | 2024-2025 | Orserdu |
| Mirati Therapeutics, INC. | $45.53 | 2023-2024 | Krazati |
| Fennec Pharmaceuticals, INC. | $42.52 | 2025 | Fyarro |
| Agios Pharmaceuticals, INC. | $41.94 | 2025 | Pyrukynd |
| Celgene Corporation | $40.18 | 2019-2024 | Pomalyst |
| Beigene USA, INC. | $40.10 | 2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $36.32 | 2025 | |
| Array Biopharma INC | $33.73 | 2020-2025 | Braftovi, Xtandi, Lorbrena |
| Avyxa Pharma, LLC | $28.00 | 2025 | |
| Beone Medicines USA, INC. | $27.00 | 2025 | Tevimbra |
| Emd Serono, INC. | $24.85 | 2024 | |
| Pharmacosmos Therapeutics INC. | $24.24 | 2024 | Cosela |
| Janssen Pharmaceuticals, INC | $23.87 | 2020 | |
| Cycle Pharmaceuticals INC | $19.25 | 2025 | Phyrago |
| Sumitomo Pharma America, INC. | $17.17 | 2025 | Orgovyx |
| Caris Mpi, INC. | $16.70 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $16.27 | 2025 | |
| Amgen INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.